## ACHC: Acadia Healthcare Company, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.32 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates). Caution: declining volume (56% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($13.15)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 4
- **Sentiment:** Bearish (Bullish: 0, Bearish: 3)

**1. Are Options Traders Betting on a Big Move in Acadia Healthcare Stock?**
- Source: TradingView â€” Track All Markets | 20251226T140846 | Bearish | Relevance: 100%
- Options traders are showing increased interest in Acadia Healthcare Company, Inc. (ACHC) stock, particularly due to high implied volatility in the Mar 20, 2026 $22.50 Put option. This suggests that the market anticipates a significant price movement for ACHC shares. However, analysts currently rate Acadia Healthcare as a Zacks Rank #5 (Strong Sell), with recent earnings estimate revisions pointing to a less optimistic fundamental outlook.

**2. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Acadia Healthcare Company, Inc. (ACHC) and Encourages Investors to Learn More About the Investigation**
- Source: KTLA | 20251225T200846 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Acadia Healthcare Company, Inc. (NASDAQ: ACHC) concerning potential corporate wrongdoing by its officers and directors. The firm is encouraging investors who purchased Acadia Healthcare securities before February 28, 2020, and still hold them, to engage with the investigation by visiting their website or contacting their office. This investigation aims to determine if there are valid claims for a class action on behalf of investors.

**3. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Acadia Healthcare Company, Inc. (ACHC) and Encourages Investors to Learn More About the Investigation**
- Source: CBS 42 | 20251225T110000 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Acadia Healthcare Company, Inc. The firm encourages investors who purchased Acadia Healthcare securities prior to February 28, 2020, and still hold them, to join the investigation. Investors can find more information about the investigation on the firm's website or by contacting their client relations team.

**4. Is Acadia Healthcare (ACHC) Now Undervalued After Its Steep 1-Year and 3-Year Share Price Declines?**
- Source: Simply Wall Street | 20251225T080921 | Somewhat-Bullish | Relevance: 96%
- Acadia Healthcare (ACHC) has seen significant share price declines over the past one and three years, and more recently over 90 days, despite continued revenue and profit growth. Trading at a substantial discount to analyst targets, the company's valuation narrative suggests it is 43.5% undervalued with a fair value of $25.32, driven by facility expansion and strategic partnerships, though risks like softer Medicaid volumes and legal costs could impact future performance.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 9)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $17 | $22 | -23% |
| 2025-12-04 | Barclays | $14 | $17 | -18% |
| 2025-12-03 | RBC Capital | $19 | $22 | -14% |
| 2025-12-03 | Cantor Fitzgera | $17 | $22 | -23% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Neutral |
| 2025-12-04 | Barclays | main | Equal-Weight |
| 2025-12-03 | RBC Capital | main | Outperform |
| 2025-12-03 | Cantor Fitzgera | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.02M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 9 / 0 |

**Top Holders:**
- Blackrock Inc.: 11.9% (+20.4%)
- Vanguard Group Inc: 10.2% (+7.8%)
- Wellington Managemen: 10.2% (+11.8%)
- FMR, LLC: 6.6% (+2.2%)
- Khrom Capital Manage: 5.5% (+103.0%)

### Key Risks

1. High short interest (21.5%, 4.8 days to cover): squeeze risk or crowded bearish bet.
2. Long-term trend broken: trading 33.9% below SMA200.
3. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.32 suggests fair value with growth premium. Analyst sentiment negative (9 target cuts vs 0 raises). Institutional flow bullish (9 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.4B |
| Beta | 0.90 |
| 52W Range | $12.63 - $47.08 |
| Short Interest | 21.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.32 |
| Forward P/E | 7.4 |
| Current P/E | 7.0 |
| YoY Growth | -5.3% |
| EPS Direction | FALLING |

### Technicals

MRS_20 strengthening from -5.0% to -1.5% (+3.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.5pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.7%) - potential reversal signal. Below SMA200 (0.66x), long-term trend not supportive. RSI neutral at 42. Volume at 56% of 20MA suggests lack of conviction. OFD pattern: +MLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.47% (CS: 32) | Neutral |
| RSI_14 | 41.9 | Neutral |
| MACD Histogram | 0.23 | Bullish |
| vs SMA20 | 0.995x | Below |
| vs SMA50 | 0.828x | Below |
| vs SMA200 | 0.661x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $14.69
- **Stop Loss:** $13.15 (10.5% risk)
- **Target:** $17.77 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 857
- **Position Value:** $12,589.33
- **Portfolio %:** 12.59%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-26 (Est: $0.13)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.66 | $0.72 | +9.2% |
| 2025Q2 | $0.71 | $0.83 | +17.4% |
| 2025Q1 | $0.36 | $0.40 | +12.0% |
| 2024Q4 | $0.71 | $0.64 | -10.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*